Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Veracyte to Acquire HalioDx, Solidifying Global Leadership in Cancer Diagnostics     Learn More
Skip to content
OVERVIEW
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.

OVERVIEW

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 2, 2021-- Details of the Raymond James Human Health Innovation Conference have been corrected. The updated release reads: VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company,
View HTML
Toggle Summary *UPDATED WITH NEW TIME**: Veracyte to Present at the 2018 UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the 2018 UBS Global Healthcare Conference on Wednesday, May 23, 2018 at 9:00 a.m. Eastern Time in New York, NY .
View HTML

Events

Date Event Details
Summary Toggle Jun 23, 2021 2:40 PM EDT
Raymond James Human Health Innovation Conference

Presentations

Title Documents

Corporate Presentation June 2021